lobbying_filings_raw: ccdde4c8-5ef7-4c04-9433-ccd4e8f732d8
This data as json
| filing_uuid | filing_type | registrant_id | registrant_name | client_id | client_name | filing_year | filing_period | received_date | amount_reported | is_amendment | is_no_activity | is_termination | raw_json |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ccdde4c8-5ef7-4c04-9433-ccd4e8f732d8 | Q1 | 400693064 | RED+BLUE STRATEGIES | 194283 | COHERUS BIOSCIENCES | 2020 | first_quarter | 2020-04-12T14:44:52.997000-04:00 | 60000.0 | 0 | 0 | 0 | {"url": "https://lda.senate.gov/api/v1/filings/ccdde4c8-5ef7-4c04-9433-ccd4e8f732d8/", "filing_uuid": "ccdde4c8-5ef7-4c04-9433-ccd4e8f732d8", "filing_type": "Q1", "filing_type_display": "1st Quarter - Report", "filing_year": 2020, "filing_period": "first_quarter", "filing_period_display": "1st Quarter (Jan 1 - Mar 31)", "filing_document_url": "https://lda.senate.gov/filings/public/filing/ccdde4c8-5ef7-4c04-9433-ccd4e8f732d8/print/", "filing_document_content_type": "text/html", "income": "60000.00", "expenses": null, "expenses_method": null, "expenses_method_display": null, "posted_by_name": "Melanie Nathanson", "dt_posted": "2020-04-12T14:44:52.997000-04:00", "termination_date": null, "registrant_country": "United States of America", "registrant_ppb_country": null, "registrant_address_1": "601 13th Street NW", "registrant_address_2": "Suite 290 North", "registrant_different_address": false, "registrant_city": "Washington", "registrant_state": "DC", "registrant_zip": "20005", "registrant": {"id": 400693064, "url": "https://lda.senate.gov/api/v1/registrants/400693064/", "house_registrant_id": null, "name": "RED+BLUE STRATEGIES", "description": "Health Care Consulting", "address_1": "975 F St NW", "address_2": "Suite 550", "address_3": null, "address_4": null, "city": "Washington", "state": "DC", "state_display": "District of Columbia", "zip": "20004", "country": "US", "country_display": "United States of America", "ppb_country": "US", "ppb_country_display": "United States of America", "contact_name": "MELANIE NATHANSON", "contact_telephone": "+1 202-258-9381", "dt_updated": "2026-02-25T17:01:10.141217-05:00"}, "client": {"id": 194283, "url": "https://lda.senate.gov/api/v1/clients/194283/", "client_id": 176, "name": "COHERUS BIOSCIENCES", "general_description": "Developer of biosimilar theraputics", "client_government_entity": false, "client_self_select": null, "state": "CA", "state_display": "California", "country": "US", "country_display": "United States of America", "ppb_state": "CA", "ppb_state_display": "California", "ppb_country": "US", "ppb_country_display": "United States of America", "effective_date": "2018-08-01"}, "lobbying_activities": [{"general_issue_code": "PHA", "general_issue_code_display": "Pharmacy", "description": "H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act - Issues related the COVID-19 that impacts small businesses as well as need for cancer medications for patients.\n\nH.R. 6201 - Families First Coronavirus Response Act - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. \n\nH.R. 748 - The CARES Act - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. \n\nH.R. 1865 - Further Consolidated Appropriations Act, 2020 - Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place. \n\nH.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace.\n\nS. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. \n\nIssues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards.", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 54544, "prefix": "ms", "prefix_display": "MS.", "first_name": "MELANIE", "nickname": null, "middle_name": "JAN", "last_name": "NATHANSON", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}, {"lobbyist": {"id": 145382, "prefix": "ms", "prefix_display": "MS.", "first_name": "MEGAN", "nickname": null, "middle_name": "HAUCK", "last_name": "MARSHALL", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 34, "name": "Health & Human Services, Dept of (HHS)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}], "conviction_disclosures": [], "foreign_entities": [], "affiliated_organizations": []} |